David A. Siegel Aligos Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $22,962 - $35,088	-25,800 Reduced 32.99%	52,400 $50,000
Q1 2023 May 15, 2023	SELL	$0.87 - $2.11 $3,741 - $9,073	-4,300 Reduced 5.21%	78,200 $68,000
Q4 2022 Feb 14, 2023	SELL	$0.89 - $28.0 $31,150 - $980,000	-35,000 Reduced 29.79%	82,500 $78,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $5,618 - $145,750	5,300 Added 4.72%	117,500 $129,000
Q2 2022 Aug 15, 2022	BUY	$1.04 - $2.14 $51,480 - $105,930	49,500 Added 78.95%	112,200 $136,000
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $97,552 - $572,180	46,900 Added 296.84%	62,700 $135,000
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $8,036 - $12,383	-700 Reduced 4.24%	15,800 $188,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $240,405 - $292,380	16,500 New	16,500 $256,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.